A Phase II, randomized, double-blind, placebo-controlled, 2-part study to evaluate the safety, tolerability, pharmacokinetics, clinical response, and antiviral activity of orally administered study drug regimens in hospitalized or non-hospitalized infants and children aged 28 days to 24 months infected with RSV (respiratory syncytial virus).
Explore related content and topics
White Paper
Global Pediatric Drug Development Collaboration Part One
The pharmaceutical industry is unlike any other industry in that the products manufactured can dramatically improve, and even save, lives. This is…
View Resource
Blog
How to Improve Access to New Medicine for Adolescents
Read Story
Blog
Ensuring Children’s Voices are Heard in Clinical Trials
World Children’s Day at PRA Health Sciences recognizes children’s rights to safe and effective treatments. This year, the teams from PRA’s Center for…
Read Story
View all related content and resources for Pediatrics
Explore Insights